Iontophoretic transdermal delivery and control of adverse side-effects
 A method is disclosed for iontophoretically removing any compound that is capable of causing skin irritation or other harmful effects. More specifically, a bipolar iontophoretic transdermal delivery method is disclosed that includes a reversal phase for controlling the iontophoretic transdermal delivery of pharmaceutical compounds while reducing or eliminating skin irritation and terminating the pharmacological or toxicological effects in skin of drugs/cosmetics/active ingredients which form a drug depot in the skin after passive or iontophoretic application. 
Novartis Finance Corp.
A A
A61N A61N
inventional inventional
Parminder Bobby Steven Minh Ann Reese
Singh Dinh Comfort